Michael Niederweis, Ph.D., and Cynthia Owsley, Ph.D., who collectively hold 23 patents, have been recognized for approaches to DNA sequencing and detection of impaired dark adaptation, respectively.

Rothenberg’s innovative, FDA-approved technology will improve cardiac health through enhanced treatment and prevention.

Yager’s journey as a Blazer is filled with institutional, national and international recognition; her most recent milestone is her unique patented catalytic reactor for NASA missions that has multiple applications in various other industries.

Blazer Bridge Fund provides financial support to innovative ideas and inventions by the UAB community, encouraging advanced discovery. 

This live biotherapeutic product, tested in mouse models, shows promise in addressing common pathways of lung disease progression.

The novel drug TIX100 functions differently from any approved diabetes drug to promote proper islet cell function.

Fobian developed Retraining and Control Therapy, or ReACT, to help patients with functional neurological disorder, or FND, which affects an estimated 300,000 Americans.

Ninety-two percent of evaluable patients treated with INB-200 exceeded a median progression-free survival of seven months. Glioblastoma multiforme is the most aggressive type of cancer originating in the brain.

Awards and honors continue for the PRCA/PRSSA at UAB chapter, where students put their classroom learning into real-world practice, preparing them for careers and vaulting them into the professional world.

National conference hosted by UAB attracts entrepreneur educators from around the nation to Birmingham.

UAB received the IEP Innovation award, recognizing exemplary initiatives spurring innovation, entrepreneurship and technology-based economic development.

This record-breaking funding marks a 73 percent growth in research awards over nine years. 

Vivek Lal, M.D., associate professor in the Department of Pediatrics at UAB Heersink School of Medicine and the founder of both ResBiotic Nutrition and Alveolus Bio, was given the 2023 Award for Excellence in Entrepreneurship.

The Blazer Bridge Fund is intended to identify and assist in the development of promising ideas, discoveries, innovations and/or technologies from UAB faculty and staff that have commercial potential. 

IN8bio has opened a new Birmingham facility, a 10,000-square-foot advanced research and development laboratory in the Martin Biscuit Building at Pepper Place.

The spinoff company, IN8bio Inc., uses proprietary drug-resistant immunotherapy licensed in part from UAB. Glioblastoma is the most aggressive type of cancer originating in the brain.

The funding from Alabama Innovation Corporation will help UAB startups make a profound impact in the biotechnology industry.

The Zorro-Flow Inc. is the newest startup from the UAB Harbert Institute for Innovation and Entrepreneurship. The device is the first external catheter to collect urine effectively, safely and comfortably from critically ill female neonates and children.

All of the newly diagnosed glioblastoma multiforme patients enrolled in a Phase 1 clinical trial have exceeded both their median and expected progression-free survivals. Two patients, to date, have exceeded their expected overall survival.

This therapy, using sustained release of nitric oxide, may be a novel, efficient and safe way to prevent and treat multiple metabolic diseases.